Knight Therapeutics Inc.

Total Valuation

Knight Therapeutics Inc. carries a market capitalization of 587.23M, placing it among publicly traded companies globally. Its enterprise value stands at 563.64M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Knight Therapeutics Inc. currently has 99.65M shares outstanding.

Valuation Ratios

Knight Therapeutics Inc. trades at a trailing price-to-earnings ratio of 1,502.13. The price-to-sales ratio is 1.50, and the price-to-book ratio stands at 0.85.

Enterprise Valuation

On an enterprise value basis, Knight Therapeutics Inc. trades at an EV/EBITDA multiple of 13.38 and an EV/FCF ratio of 9.10. The EV/Sales ratio of 1.47 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 46.97 provides insight into valuation relative to core operating earnings.

Financial Position

Knight Therapeutics Inc. maintains a current ratio of 2.47, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.73, indicating elevated leverage, while an interest coverage ratio of 4.96 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Knight Therapeutics Inc. has paid -7.91M in income taxes, reflecting an effective tax rate of 86.02.

Stock Price Statistics

Knight Therapeutics Inc.'s stock has gained approximately 40.94118% over the past 52 weeks. The 50-day moving average sits at 5.64, while the 200-day moving average is 4.70.

Income Statement

Over the trailing twelve months, Knight Therapeutics Inc. generated 384.56M in revenue and converted that into 383,000.00 in net income, yielding earnings per share of 0.00. EBITDA reached 42.12M, while operating income came in at -8.96M.

Balance Sheet

Knight Therapeutics Inc. holds 116.42M in cash and equivalents against 104.74M in total debt, resulting in a net debt position of 19.85M. Total book value stands at 676.85M, with working capital of 226.18M providing operational flexibility.

Cash Flow

Knight Therapeutics Inc. produced 30.41M in operating cash flow over the past twelve months. After subtracting -31.95M in capital expenditures, free cash flow totaled -1.54M - equivalent to -0.02 per share.

Margins

Knight Therapeutics Inc. operates with a gross margin of 42.92, reflecting its pricing power and cost economics. The operating margin of -2.33 and net profit margin of 0.10 provide insight into operational efficiency.

Dividends & Yields

Scores

Knight Therapeutics Inc. posts an Altman Z-Score of 2.73, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.